📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. A one-page introduction to the product: its pharmacologic class, proposed indication, and dosage form.
Why it exists. The CTD opens with a brief orientation so a reviewer knows, in a paragraph, what the drug is and what is being claimed before diving into the detailed summaries.
How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.
Format & governing standard. ICH M4 §2.2
| Field | Value |
|---|---|
| Document ID | M22 |
| Version | 2.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard | ICH M4 §2.2 |
| Confidentiality | Confidential — portfolio use |
| Version | Date | Author | Summary of Change |
|---|---|---|---|
| 1.0 | 2026-06-29 | Regulatory |
No comments yet. Be the first to say something!
| Initial introduction |
| 2.0 | 2026-07-05 | Regulatory | Expanded to full §2.2 scope (development/regulatory context, designations, application basis) |
This marketing application concerns GLPI-103, a first-in-class synthetic peptide dual agonist of the GLP-1 and Apelin (APJ) receptors, developed by Virtual Biopharma Inc.
[MOCK].[MOCK].GLPI-103 was developed to combine the established glycaemic and weight benefits of GLP-1 receptor agonism with APJ-mediated improvements in insulin sensitivity, endothelial and myocardial function, and inflammation, differentiating it on cardiometabolic positioning versus GLP-1-only therapies. The program comprises a nonclinical package (Modules 2.4/2.6/4), a clinical-pharmacology program (Phase 1 SAD/MAD and Phase 2 dose-finding; Modules 2.7.1/2.7.2/5.3), and a pivotal Phase 3 confirmatory study (GLPI103-301) demonstrating superiority over oral semaglutide on HbA1c change from baseline at Week 52, with a class-consistent, manageable safety profile (Modules 2.5/2.7.3/2.7.4/5.3.5). Interactions with health authorities (Pre-IND, End-of-Phase-2, and Pre-NDA/Pre-submission meetings) and any expedited-program considerations are summarized in Module 1 (regional).
The application seeks marketing authorization on the basis of the demonstrated benefit–risk in the target population (Module 2.5.6). The dossier follows the ICH Common Technical Document format, with Module 2 summaries and overviews, Module 3 quality, Module 4 nonclinical study reports, and Module 5 clinical study reports and data, and region-specific Module 1 content prepared for the FDA, EMA, and MFDS. The nonclinical and CMC content is deep-knowledge mock ([MOCK]), while the clinical thread is anchored to one simulated Phase 3 dataset that is reconciled across the dossier.